Ranibizumab for the Treatment of Macular Edema Associated with Perfused Central Retinal Vein Occlusions

Pieramici, Dante J.; Rabena, Melvin; Castellarin, Alessandro; Nasir, Maʼan; See, Robert F.; Norton, Tamara; Sanchez, A.; Risard, Sarah M.; Avery, Robert L.

doi:10.1016/j.ophtha.2008.06.021

Cited by 91 publications

(66 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been successfully used in off-label treatment of CNV in other retinal diseases in which VEGF is upregulated [4][5][6][7][8]: diabetic retinopathy, pathologic myopia, angioid streaks and central venous occlusion. Treatment for traumatic CNV has been recently described with anti-VEGF [8], but with a different drug, bevacizumab.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch’s membrane rupture

Liang

Puche

Soubrane

et al. 2009

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch’s membrane rupture

Liang

Puche

Soubrane

et al. 2009

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…With ranibizumab, Pieramici et al [52] designed a study following the scheme of the PIER Study, i.e. the first 3 injections monthly and then after 6 and 9 months, if needed (persistent macular edema).…”

Section: Treatmentmentioning

confidence: 99%

“…Funk et al [38] found reduced VEGF levels in long-term RVO, so there would be a benefit of early intervention. Fourth, although there is an initial reduction of the central retinal thickness, it is followed by a rebound effect of the macular edema, maybe caused by an upregulation of the VEGF receptors [52]. Fifth, another important limit is the still high percentage of patients that have no VA improvement with the treatment; according to Hoeh et al [62], one third of the CRVO/BRVO patients.…”

Section: Treatmentmentioning

confidence: 99%

Retinal Vein Occlusion: Current Treatment

Lattanzio¹,

Gimeno

Parodi³

et al. 2010

Ophthalmologica

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) is a pathology noted for more than 150 years. Although a lot has been written on the matter, it is still a frequent condition with multifactorial etiopathogenesis with many unclear aspects. The RVO pathogenesis has varied systemic and local implications that make it difficult to elaborate treatment guidelines. The management of the patient with RVO is very complex and a multidisciplinary approach is required in order to identify and correct the associated risk factors. Laser therapy remains the gold standard in RVO, but only modest functional improvement has been shown in branch retinal occlusion forms. Multicenter studies of intravitreal drugs present them as an option to combine with laser. Anti-vascular endothelial growth factor, corticosteroids and sustained-release implants are the future weapons to stop disease progression and get a better visual outcome. Consequently, it is useful to clarify some aspects of the pathology that allow a better patient management.

show abstract

“…Within each group, there was a spectrum from moderately high to very high levels of VEGF and there was an inverse correlation between VEGF level and visual outcome. Other pilot trials investigating the effect of ranibizumab in patients with CRVO also showed substantial benefit [12,13]. …”

Section: Treatmentmentioning

confidence: 99%

Anti-Vascular Endothelial Growth Factor Treatment for Retinal Vein Occlusions

Campochiaro¹

2012

Ophthalmologica

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) encompasses two conditions: central RVO, in which the major outflow vessel of the retina is obstructed, and branch RVO, in which a proximal branch of the central retinal vein is obstructed. In both conditions, there is increased intraluminal and interstitial pressure throughout the retina drained by the obstructed vessels, resulting in reduced arterial perfusion, which is exacerbated by preexistent arterial insufficiency, and in variable amounts of retinal ischemia. Retinal ischemia causes increased production of vascular endothelial growth factor (VEGF), which causes vascular leakage and macular edema. High levels of VEGF also promote retinal hemorrhages and exacerbate capillary nonperfusion. Intraocular injections of a VEGF-binding protein reduce vascular leakage, resulting in improvement in macular edema, accelerate resorption of retinal hemorrhages, and prevent worsening of capillary nonperfusion. The ideal regimen has not been defined, but it appears that monthly injections early in the course control edema and may help to limit disease severity in a large percentage of patients. Over time, treatment should be individualized based upon timing and severity of recurrent edema and/or progression of nonperfusion. The role of adjunctive treatments is yet to be defined, but it is clear that VEGF antagonists provide excellent first-line treatment that has dramatically improved visual outcomes in patients with RVO.

show abstract

Ranibizumab for the Treatment of Macular Edema Associated with Perfused Central Retinal Vein Occlusions

Cited by 91 publications

References 22 publications

Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch’s membrane rupture

Intravitreal ranibizumab for choroidal neovascularization related to traumatic Bruch’s membrane rupture

Retinal Vein Occlusion: Current Treatment

Anti-Vascular Endothelial Growth Factor Treatment for Retinal Vein Occlusions

Contact Info

Product

Resources

About